Hyperfibrinogenemia and Metastasis in Gastric Cancer
Author Information
Author(s): Yamashita Hiroharu, Kitayama Joji, Kanno Nobuko, Yatomi Yutaka, Nagawa Hirokazu
Primary Institution: The University of Tokyo, Graduate School of Medicine
Hypothesis
Higher plasma fibrinogen levels might be a good clinical marker of metastatic disease and worse clinical outcome in gastric cancer.
Conclusion
Hyperfibrinogenemia is associated with increased lymphatic and hematogenous metastasis in T2 gastric cancer, indicating it could be a useful biomarker for predicting worse clinical outcomes.
Supporting Evidence
- Patients with hyperfibrinogenemia showed worse clinical outcomes in T2 gastric cancer.
- Hyperfibrinogenemia was independently associated with lymph node and liver metastasis.
- There was no correlation of plasma fibrinogen level with prognosis in T3/T4 gastric cancer.
Takeaway
If a patient with gastric cancer has high fibrinogen levels, it might mean their cancer is spreading more and they could have a worse outcome.
Methodology
Retrospective examination of preoperative plasma fibrinogen levels in 405 patients who underwent surgery for advanced gastric cancer.
Potential Biases
Potential bias due to the exclusion of patients with acute inflammatory diseases, liver cirrhosis, and chronic renal failure.
Limitations
The study is retrospective and may be affected by confounding factors such as inflammation and other health conditions.
Participant Demographics
Patients with advanced gastric cancer who underwent surgery, with a focus on T2 and T3/T4 classifications.
Statistical Information
P-Value
0.0032 for lymph node metastasis, 0.0147 for liver metastasis
Confidence Interval
2.342 (1.330-3.546) for lymph node metastasis, 2.933 (1.236-6.944) for liver metastasis
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website